Treatment GuideJust DiagnosedSex & DatingAfrican AmericanStigmaAsk the HIV DocPrEP En EspañolNewsVoicesPrint IssueVideoOut 100
CONTACTCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2025 Pride Publishing Inc.
All Rights reserved
All Rights reserved
Scroll To Top
By continuing to use our site, you agree to our Private Policy and Terms of Use.
There are more than seven dozen anti-HIV drug candidates in various stages of testing. While some will be unsuccessful, the potential for newly developed medications as well as medication classes is better than ever before in the almost 25 years of the AIDS pandemic. The two main new drug classes in development are integrase inhibitors and maturation inhibitors. Integrase inhibitors interfere at the viral replication step in which HIV's genetic information is inserted into the host cell's DNA, thereby enabling the cell to start making copies of the virus. Integrase inhibitors target and disable HIV's integrase enzyme, which plays a key role in this replication step. Maturation inhibitors interfere with the final stages of HIV replication, in which viral copies are assembled and exit an infected cell. These drugs would prevent the virus from properly assembling, from forming a protective outer coat, or from emerging--also known as budding--from human cells. Below is a list of anti-HIV drugs in development, listed alphabetically in respective drug categories. Each listing also includes the drug's stage of development and company that is working on the medication. Entry Inhibitors AMD-070 (CXCR4 blocker); phase II; Anormed. AMD-887 (CCR5 blocker); preclinical; Anormed. AMD3100 (CXCR4 blocker); phase I; Anormed. Betulinic acid derivatives (entry, maturation inhibitors); preclinical; University of North Carolina-Duke-Vanderbilt. BMS-043; phase I/II; Bristol-Myers Squibb. BMS-378806 (gp120 blocker); phase I; Bristol-Myers Squibb. CCR5mAb004 (CCR5 blocker); preclinical; Human Genome Sciences. D5 (artificial gp41 blocker); preclinical; Merck. GBV-C (virus increases chemokines,including CCR5 blockers); preclinical; University of Iowa. GSK-873140 (CCR5 blocker); phase II; GlaxoSmithKline. IC9564; preclinical; Duke University. KRH-2731 (CXCR4 blocker); preclinical; Kureha. Maraviroc/UK-427 (CCR5 blocker); phase II; Pfizer. MDX-010; phase I; Medarex. NB-2 (gp41 blocker); preclinical; Shibo-Kumar. NB-64 (gp41 blocker); preclinical; Shibo-Kumar. PRO-140 (monoclonal antibody); preclinical; Progenics. PRO-542 (attachment inhibitor); phase II; Progenics. RC-112; preclinical; CDC's AIDS, STD, and TB Laboratory Research. Retrocyclin-1; preclinical; CDC's AIDS, STD, and TB Laboratory Research. SP-01 A; phase I/II; Samaritan. TAK-652 (CCR5 blocker); preclinical; Takeda. TNX-355 (monoclonal antibody); phase I/II; Tanox-Biogen. UMIST; preclinical; Genetic Innovation. Vicriviroc/SCH-D (CCR5 blocker); phase II; Schering Plough. Integrase Inhibitors Carbazole derivative; preclinical; Japan's National Institute of Infectious Diseases. GSK-810871; preclinical; GlaxoSmithKline. Indolicidin; preclinical; National Cancer Institute. JTK-303; phase I/II; Gilead-Japan Tobacco. L-810810; phase I; Merck. Styrylquinoline derivatives; preclinical; BioAlliance Pharma. V-165; preclinical; Belgium's Rega Institute. Maturation Inhibitors Betulinic acid derivatives (entry, maturation inhibitors); preclinical; University of North Carolina-Duke-Vanderbilt. Chloroquinine; preclinical; Catholic University of Rome. enJS56A1; preclinical; University of Georgia. PA-457 (capsid inhibitor); phase II; Vitex. Nonnucleoside Reverse Transcriptase Inhibitors BILR 355 BS; preclinical; Boehringer-Ingelheim. Calanolide A; phase II; Advanced Life Sciences. Capravirine; phase II; Pfizer. DOT (dioxolane thymidine); phase I; University of Georgia. GSK-695634; phase I; GlaxoSmithKline. KP1212; phase I; Koronis. MIV-150; phase II; Medivir. MIV-170; preclinical; Medivir. NVP C-8 derivatives; preclinical; Boehringer-Ingelheim. Oligodeoxi nucleotides; preclinical; University of Zurich. S-DABO derivatives; preclinical; China's Fudan University. SMP-610; preclinical; Advanced Life Sciences. SMP-717; preclinical; Advanced Life Sciences. Thiazol derivatives; preclinical; Japan's Institute for Virus Research. TMC-125 (etravirine); phase II; Tibotec-Johnson and Johnson. TMC-278 (diarylpyrimidine or DAPY); phase II; Tibotec. Tricyclic NNRTI; preclinical; Bristol-Myers Squibb. Nucleoside Reverse Transcriptase Inhibitors Alovudine (MIV-310); phase II; Medivir-Boehringer-Ingelheim. Amdoxovir (DAPD); phase II; RFS Pharm. BPH-218; preclinical; University of Pittsburgh. Compound X; preclinical; Tibotec. Dinucleoside polyphosphates; preclinical; University of Miami. Elvucitabine (ACH-126); phase II; Achillion. GSK-204937; phase I; GlaxoSmithKline. KMMP05; preclinical; National Cancer Institute. MIV-210; phase I/II; Medivir-GlaxoSmithKline. Racivir; phase I/II; Pharmasset. Reverset (D-D4FC); phase II; Pharmasset-Incyte. SPD-754; phase I/II; Avexa. Protease Inhibitors A-681799; preclinical; Abbott Laboratories. AG-1859; phase II; Pfizer. Aptivus (tipranavir); Approved by FDA on June 22; Boehringer-Ingelheim. GSK-640385 (VX-385); phase I/II; GlaxoSmithKline. PPL-100; preclinical; Procyon Biopharma. TMC-114; phase II; Tibotec-Johnson and Johnson. UIC02031; preclinical; Kumamoto University. Others ACH-CIC (capsid inhibitor complex); preclinical; Achillion. BAY 50-4798 (interleukin-2 selective agonist); phase I; Bayer. BL-1050 (regulatory protein inhibitor); preclinical; BioLine Rx. CDK inhibitor; preclinical; Gilead Sciences. CNI-1493 (rev inhibitor); preclinical; Heinrich Pette Institute. Curcumin/diferuloylmethane (tat inhibitor); preclinical; India's Jawaharlal Nehru Center. HGTV43 (gene regulation-editing inhibitor); phase I; Enzo. MDI-P (electrolyzed free radical); preclinical; Medical Discoveries. Mifepristone (glucocorticoid antagonist); phase I; University of Pittsburgh. Resveretrol (Egr1 gene activator); preclinical; National Cancer Institute. RSC-1838; preclinical; GlaxoSmithKline-Shionogi. RWJ67567 (p38 inhibitor); preclinical; University of Pennsylvania-Johnson and Johnson. siRNA molecule; preclinical; CombiMatrix. TRIM5-alpha (capsid inhibitor); preclinical; Dana Farber Cancer Institute-NAIAD. VRX496 (antisense lentiviral vector); phase I; VIRxSYS.
From our Sponsors
Most Popular
Lexi Love comes out as HIV+ after Trump deletes federal resources
January 23 2025 11:23 AM
Ricky Martin delivers showstopping performance for 2024 World AIDS Day
December 05 2024 12:08 PM
Trump's orders prompt CDC to erase HIV resources
January 31 2025 5:29 PM
California confirms first case of even more deadly mpox strain
November 18 2024 3:02 PM
This long-term HIV survivor says testosterone therapy helped save his life.
December 16 2024 8:00 PM
Plus: Featured Video
Latest Stories
HRC holds 'die-in' to protest Trump health care cuts
April 28 2025 2:11 PM
The Talk Season 5 premieres this spring with HIV guidance for the newly diagnosed
March 26 2025 1:00 PM
Jess King is here to help you live your happiest, healthiest life yet
March 24 2025 4:35 PM
Gerald Garth is keeping people of color happy and healthy through trying times
March 11 2025 3:38 PM
'RuPaul's Drag Race' star Trinity K Bonet quietly comes out trans
December 15 2024 6:27 PM
Hollywood must do better on HIV representation
December 01 2024 9:00 AM
Post-election blues? Some advice from mental health experts
November 08 2024 12:36 PM
Two right-wing Supreme Court justices signal they may uphold access to PrEP and more
April 21 2025 4:10 PM
500,000 Children at Risk: PEPFAR Funding Crisis
April 08 2025 3:51 PM
Discover the power of Wellness in your life
March 26 2025 12:41 PM
BREAKING NEWS: Trump admin moves to end federal HIV prevention programs
March 18 2025 6:10 PM
Celebrating Black History Month with our annual African American issue
February 01 2025 3:28 PM
Plus nominated for 2025 GLAAD Media Award
January 22 2025 12:42 PM
AIDS Memorial Quilt displayed at White House for the first time
December 02 2024 1:21 PM
Broadway's best raise over $1 million for LGBTQ+ and HIV causes
April 03 2025 7:15 PM
Season 4 of The Switch on resilience & radical self-love returns this spring
March 26 2025 12:20 PM
Tyler TerMeer vows to continue to fight for health care for all
January 28 2025 3:00 PM
A camp for HIV-positive kids is for sale. Here's why its founder is celebrating
January 02 2025 12:21 PM
Decades of progress, uniting to fight HIV/AIDS
December 01 2024 12:30 PM
Climate change is disrupting access to HIV treatment
November 25 2024 11:05 AM